Publications
T-Cells
G-Rex®24 Well Plate
Publication Date: October 4, 2024
Human CD4+ memory T cells can be engineered to act as a long-lived source of the enzyme alpha-L-iduronidase (IDUA) in a mouse model of mucopolysaccharidosis type I. CRISPR-Cas9 with an rAAV6 donor inserted an IDUA cassette at the AAVS1 locus, giving up to about 50% RQR8-positive cells. A single intraperitoneal dose of 10 million engineered cells into immunodeficient NSG-MPS I mice produced IDUA activity in plasma and tissues, and the cells persisted at least 22 weeks in blood. Tissue glycosaminoglycan content fell in several organs, and LAMP-1 staining decreased in liver and brain. Engineered cells were also detected in brain tissue. Effects waned over time, and spatial learning in the Ba…
Publications
TCR T Cells
G-Rex®10M
Publication Date: October 3, 2024
A TCR cloned from the MR1-restricted clone MC.7.G5 and expressed in human T cells as 7G5.TCR-T did not show pan-cancer activity; it recognized cells carrying the rare MR1*04 allele, including healthy cells. Only nine of 133 cancer cell lines (7%) gave IFN-γ above 50 pg/ml, and responses to MR1*04-bearing targets were two- to 110-fold greater than to other lines. Monocytes and B cells from MR1*01/*04 donors, but not MR1*01 homozygous donors, triggered IFN-γ and granzyme B release. Overexpressing MR1*01 at supraphysiological levels also drove reactivity, while the bacterial ligand Ac-6-FP abrogated responses to MR1*04 lines. Two 7G5-like TCRs, A4 and C1, behaved similarly, producing IFN-γ a…
Publications
VST Cells
Publication Date: September 25, 2024
Over the past three decades, adoptive transfer of non-engineered virus-specific T cells (VSTs) has proven safe and clinically active against viral infections in immunocompromised patients, mainly after allogeneic stem cell transplantation. This review compares manufacturing routes: direct isolation by multimer selection or IFNγ capture, and ex vivo expansion with antigen-presenting cells, including multivirus products and cord blood-derived lines. Third-party banked VSTs offer rapid access; in a multicenter trial of 50 patients given banked lines, the cumulative response rate at 6 weeks was 74%. A retrospective comparison of 145 patients found similar response rates for stem cell donor-de…
Publications
CAR T Cells
G-Rex®6 Well Plate
Publication Date: September 24, 2024
Swapping only the hinge and transmembrane domains of a third-generation GUCY2C CAR, from CD28 to CD8α, improved anti-tumor potency against colorectal cancer. Both constructs shared the same scFv and CD28/4-1BB/CD3ζ signaling domains, and donor T cells transduced with either one expanded equally over 12 days, kept comparable viability, memory and exhaustion profiles, and displayed similar numbers of CAR molecules per cell. The CD8α version bound soluble GUCY2C with an EC50 of 7.78–8.26 nM versus 11.3–13.0 nM, released more IL-2, IFNγ and granzyme B after antigen exposure, and cleared low antigen-expressing LoVo cells significantly better. In mice bearing intraperitoneal T84 tumors, 70.6% o…
Publications
NK Cells
G-Rex®10
Publication Date: September 16, 2024
Pre-treating acute myeloid leukemia cells with the proteasome inhibitors Bortezomib or Carfilzomib made them markedly more vulnerable to killing by allogeneic, feeder-cell-activated NK cells, and adding a CD33- or CD70-directed CAR increased that effect further. Twenty-four hours of inhibitor exposure lowered class-I HLA surface expression, raised stress-associated protein transcripts and surface levels by 48 hours, and increased NK-AML conjugate formation and interferon-gamma release. Combinatorial indices above one confirmed synergy against cell lines and six primary patient samples. In murine xenografts, a single Bortezomib dose followed one day later by activated NK cells extended med…
Publications
NK Cells
Publication Date: September 10, 2024
No non-viral delivery system yet delivers CAR transgenes to natural killer (NK) cells efficiently without compromising their viability or receptor status, according to this review of non-viral CAR-NK cell engineering. Electroporation is the most widely used method, with transfection rates of up to 90%, but primary NK cell viability after electroporation has been reported as low as 2%. Among the nanocarriers summarised, CL1H6 lipid nanoparticles gave 90% gene silencing with 90% viability in NK-92 cells, charge-altering releasable transporters gave 32% GFP expression with 78% viability in peripheral blood NK cells, and magnetic multifunctional nanoparticles delivered an EGFR-targeted CAR pl…
Publications
VST Cells
G-Rex®24 Well Plate, G-Rex®6 Well Plate
Publication Date: August 28, 2024
A bispecific anti-EGFR / HLA-A*02:01-CMVpp65 antibody armed with a monovalent IL-2 mutein (H16A, F42A), called IL-2-armored guided pMHC staging (GPS), both expanded cytomegalovirus-specific CD8+ memory T cells and redirected them against EGFR-expressing cancer cells. PBMCs from CMV-positive, HLA-A*02:01-positive donors were cultured for 14 days with 6 nM test article in 24-well G-Rex® plates. CMV tetramer-positive cells reached 79.1% of viable CD8+ T cells with Fab IL-2 GPS and 86.3% with Fc IL-2 GPS, against 35.0% for the pp65 plus IL-2 control; GPS without the mutein did not expand them. Both armored formats killed NCI-H358 target cells potently, and GPS lowered CD4+ T cell activation a…
Publications
CAR T Cells
G-Rex®24 Well Plate
Publication Date: August 27, 2024
A virus-free piggyBac system, Quantum pBac, produced CD20/CD19 dual-targeted iCasp9-regulatable CAR-T cells dominated by stem cell memory phenotype in a 10-day culture. Nucleofected T cells seeded at 1 x 10^5 per well in 24-well G-Rex® with 3 ml medium expanded 43.54-157.55-fold for six healthy donors and 57.95-198.96-fold for eight cancer patients, reaching 4.58 x 10^6 to 2.76 x 10^7 cells per well with CAR expression of 19.93-53.22 percent in patients. T stem cell memory subsets rose from 13.75 percent to 76.25 percent in CD4 and from 8.62 percent to 81.90 percent in CD8 populations, and fresh cells lysed 98.96-99.88 percent of Raji targets at a 5:1 ratio in 48 hours.
Publications
VST Cells
G-Rex®10, G-Rex®24 Well Plate, G-Rex®6 Well Plate
Publication Date: August 23, 2024
Rapidly expanded EBV-specific T cells enriched for stem cell memory T cells (TSCMs) controlled EBV-driven lymphoma in mice as well as conventional long-term EBV-CTLs, and showed greater in vivo expansion, persistence and tumor infiltration. Healthy-donor PBMCs were stimulated with a mix of 43 peptides from 15 EBV proteins and expanded for about 10 days with IL-4, IL-7 and the glycogen synthase kinase-3β inhibitor TWS-119, the condition that gave the highest TSCM proportion (~30%) and the lowest exhaustion marker levels. Compared with 4- to 5-week cultures restimulated with EBV-transformed LCLs, the rapid product yielded fewer cells but more CD4+ T cells and broader latent and lytic antige…
Publications
CAR T Cells
G-Rex®6 Well Plate
Publication Date: August 21, 2024
Allogeneic CAR T cells engineered with TALEN gene editing can be gated so that a second CAR is produced only when a first CAR meets its target in the tumor stroma. Healthy-donor T cells constitutively expressed a FAP CAR against cancer-associated fibroblasts, lost TRAC and PDCD1, and carried a mesothelin CAR integrated at PDCD1, which was induced after FAP CAR engagement, peaking at 48 h. In vitro, the cells killed nearly 100% of FAP-medium and FAP-high NCI-H226 targets but not FAP-negative ones. In NSG mice with bilateral tumors, growth was significantly reduced only in FAP-positive tumors, with no difference in FAP-negative tumors between groups. In an orthotopic triple-negative breast…
Publications
T-Cells
G-Rex®24 Well Plate
Publication Date: August 20, 2024
Single-cell DNA and surface-protein sequencing resolved on-target edits, off-target editing and chromosomal translocations cell by cell in CRISPR–Cas9-engineered CD8+ T-cell products. T cells from four healthy donors were edited to knock out TRAC, TRBC1 and TRBC2, expanded for 7 days and profiled on the Tapestri platform with 40 custom amplicons and 14 oligo-conjugated antibodies, sequencing at least 4,000 cells per run. TRAC editing ranged from 50% to 82% across donors, whereas triple mono-allelic and triple bi-allelic edits each occurred in only 2% to 5% of cells. One TRAC off-target site (TRAC-OT2) was edited more often in cells with bi-allelic TRAC edits. Four TRAC–TRBC translocations…
Publications
NK Cells, TCR T Cells
G-Rex®24 Well Plate
Publication Date: August 19, 2024
Engineering the natural killer line YT-Indy with CD8 alpha/beta, all four CD3 subunits and a recombinant TCR produced reconstituted cytotoxic effectors that delivered granzyme B to K562-based synthetic antigen-presenting cells only when a cognate peptide and HLA allele were present. Surface TCR appeared only after the CD3 helper cassette was added. Two model receptors were tested: an HSDL1 L25V neoepitope TCR restricted by HLA-C*14:03 and the MAGEA3-reactive EB81.103 TCR on HLA-A*01:01, whose signal fell after CRISPR deletion of the endogenous epitope and recovered when a minigene restored it. The effectors stored roughly 70-fold more granzyme B than primary CTLs and destroyed targets rap…
No manuscripts match your filters.